Bone Marrow Transplantation News

SALT LAKE CITY — Abatacept demonstrated efficacy among patients with steroid-refractory chronic graft-versus-host-disease, according to phase 2 study results.

SALT LAKE CITY — Eprenetapopt plus azacitidine maintenance therapy significantly improved outcomes for patients with TP53-mutated acute myeloid leukemia and TP53-mutated myelodysplastic syndrome, according to study results.

SALT LAKE CITY — Sickle cell disease increased risk for transplant-associated thrombotic microangiopathy among children who underwent hematopoietic stem cell transplantation, according to study results.

SALT LAKE CITY — Defibrotide benefitted adults and pediatric patients with severe or very severe veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation, according to study results.

Krishna Komanduri, MD, has been appointed division chief of hematology-oncology at UCSF Health.

Early in my career, I received a career development award from a scientific society to further my research on cellular therapies in hematologic malignancies.

The FDA has granted a prior approval supplement to Zydus Lifesciences Limited allowing the company to market its generic mycophenolate mofetil injection USP, 500 mg vial, following a transfer to a new manufacturing site.

Thanks to the COVID-19 pandemic, it became necessary to rethink how complex care is delivered to immunocompromised patients.

The FDA granted orphan drug designation to mocravimod for treatment of patients with acute myeloid leukemia who are undergoing allogeneic hematopoietic stem cell transplantation.

Adding romidepsin to busulfan and fludarabine reduced incidence of relapse among patients receiving allogeneic stem cell transplant for aggressive T-cell malignancies, according to results of a phase 1/phase 2 study.